Exelixis Inc Operating Lease Right-of-Use Assets
Exelixis Inc (EXEL) had Operating Lease Right-of-Use Assets of $159.04 million as of 2026-01-02, per its 10-K filed 2026-02-10.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-02-10
- 2026-01-02: Operating Lease, Right-of-Use Asset $159.04M.
- 2025-01-03: Operating Lease, Right-of-Use Asset $172.56M.
- 2023-12-29: Operating Lease, Right-of-Use Asset $233.24M.
- 2023-05-31: Operating Lease, Right-of-Use Asset $13.20M.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-01-02 | $159.04M 10-K · filed 2026-02-10 |
| 2025-01-03 | $172.56M 10-K · filed 2026-02-10 |
| 2023-12-29 | $233.24M 10-K · filed 2025-02-11 |
| 2023-05-31 | $13.20M 10-K · filed 2024-02-06 |
| 2022-12-30 | $234.81M 10-K · filed 2024-02-06 |
| 2022-06-01 | $4.30M 10-Q · filed 2022-11-01 |
| 2021-12-31 | $45.12M 10-K · filed 2023-02-07 |
| 2021-01-01 | $43.01M 10-K · filed 2022-02-18 |
| 2020-01-03 | $41.84M 10-K · filed 2021-02-11 |
| 2019-09-27 | $17.73M 10-Q · filed 2019-10-30 |
| 2019-06-28 | $16.57M 10-Q · filed 2019-07-31 |
| 2019-03-29 | $13.92M 10-Q · filed 2019-05-01 |
| 2018-12-28 | $5.87M 10-K · filed 2020-02-25 |
| 2018-09-28 | $5.99M 10-Q · filed 2018-11-01 |
| 2017-12-30 | $8.58M 10-K · filed 2019-02-22 |
| 2017-12-29 | $0.00 10-K · filed 2019-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |